The selective effects of dasatinib on NSCLC cells harboring KIBRAF suggests that the combination of BRAF inhibitors with dasatinib would be effective in WTBRAF NSCLC which would have a broader clinical application. Here, BRAF is linked to non-small cell lung carcinoma.